Messoud Ashina (Copenhagen/ DK), Dimos Mitsikostas (Athens/ GR), Faisal Mohammad Amin (Copenhagen/ DK), Pinar Kokturk (Amsterdam/ NL), Gurdal Sahin (Lund/ SE), Christoph Schankin (Bern/ CH), Paul Dorman (Newcastle upon Tyne/ GB), Patricia Pozo-Rosich (Barcelona/ ES), Leonidas Lyras (Amsterdam/ NL), Coleen Myers (West Chester, PA/ US), Andrew Ahn (West Chester, PA/ US), Cristina Tassorelli (Pavia/ IT)
Abstract text (incl. figure legends and references)
Objective: Fremanezumab, a humanised monoclonal antibody, that selectively targets calcitonin gene-related peptide (CGRP), is approved in Europe for migraine prevention in adults with ≥4 monthly migraine days (MMD). PEARL study aims to provide real-world data on effectiveness, acute medication use, and disability in patients (pts) initiating fremanezumab treatment. Here we present the second interim analysis.
Methods: PEARL is a 24-month, pan-European, prospective, observational study. Eligible pts are adults (≥18 years) diagnosed with episodic or chronic migraine (EM, CM) and starting fremanezumab treatment. The primary endpoint is the proportion of pts with ≥50% reduction from baseline (BL) in average MMD (≥50% response) during the 6 months post fremanezumab initiation. Secondary endpoints were assessed at multiple timepoints from Months 1 to 24 and include mean change from BL in: MMD; average monthly days of acute migraine medication use; disability scores (Migraine Disability Assessment [MIDAS] and 6-item Headache Impact Test [HIT-6]).
Results: 574 pts (EM, 26%; CM, 74%) were evaluated in this interim analysis; 65% had used prior anticonvulsants, 61% beta-blockers, and 51% tricyclic antidepressants for preventive treatment. For patients with data for the primary endpoint (n = 313), 56% (EM, 69%; CM, 52%) achieved ≥50% MMD response during the 6 months after fremanezumab initiation. For secondary endpoints, the mean±SD change from BL at Month 6 was –8.0±7.1 for MMD, –6.7±6.2 for average monthly days of acute migraine medication use, –52.7±58.5 for MIDAS score, –9.5±8.8 for HIT-6 score. One pt experienced a drug-related serious adverse event of dysphonia.
Conclusion: The real-world effectiveness of fremanezumab is supported by this interim analysis, with more than half of pts reporting a ≥50% reduction in MMD during the 6 months after fremanezumab initiation, improvement in other secondary outcome measures, and favorable safety profile.
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.